WAT-on-a-chip - Development of a micofluidic, microphysiologic in vitro adipose tissue model for high-throughput drug screening based on hiPSC-derived adipocytes.
WAT-on-a-chip - Development of a micofluidic, microphysiologic in vitro adipose tissue model for high-throughput drug screening based on hiPSC-derived adipocytes.
批准号:
257256526
负责人:
Professor Dr. Peter Loskill
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Fellowships
财政年份:
2014
资助国家:
德国
项目状态:
已结题
起止时间:
2013-12-31 至 2015-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Drug discovery and development is hampered by high failure rates attributed to the reliance on non-human animal models and non-physiological conditions employed during safety and efficacy testing. A fundamental problem in this inefficient process is that non-human animal models cannot sufficiently represent human biology, and more importantly, they cannot adequately recapitulate human disease states. With the discovery of patient-specific human induced pluripotent stem (iPS) cells, the tissue engineering community is now in position to develop in vitro disease-specific model tissues and organs to be used for high content drug screening and patient specific medicine. The principal goal of this project is to create a white adipose tissue (WAT) model system on a chip. WAT as a model system was chosen since it can play a major role for both drug delivery and efficacy in a variety of ways, including passive drug storage, side-effects of other tissue targeting drugs, and the efficacy of adipose targeted drugs. The WAT-on-a-chip will be based on a microfluidic platform that mimics the dimensions and cellular arrangement of minimal elements of human adipose tissue. This microfluidic design will allow excellent control over media perfusion via continuous flow, which also allows similar control in delivering any soluble drug to the adipose tissue model. Furthermore, the platform will allow for continuous monitoring, sampling, and probing of the tissue model. Secondary goals of this project include (i) the integration of a glucose sensor into the platform to enable live monitoring of glucose level, indicating functionality and drug-response of the tissue, and (ii) differentiation of human iPS cells to functional adipocytes within the developed platform. The final platform is envisioned to be extremely versatile and to be applicable for both fundamental studies of adipose tissue and the screening of drugs for therapeutic diagnostic and applications.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
CHIP泛素化修饰CIB1结合PLK2介导线粒体功能障碍重塑肺腺癌糖代谢调 控肿瘤细胞转移
-
批准号:2026JJ50309
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:周燕武
-
依托单位:
CHIP通过泛素化修饰RIP3调控巨噬细胞
坏死性凋亡在角膜新生血管形成中的作
用
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:叶一明
-
依托单位:
Triptonide 通过 CHIP 介导的蛋白酶体途径清
除野生型IDH1 急性髓系白血病细胞的机制
研究
-
批准号:TGY24H080029
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:杨琳琳
-
依托单位:
TAT-CHIP 融合蛋白减轻脓毒症心功能障碍的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:30.0万元
-
批准年份:2024
-
负责人:吴森泉
-
依托单位:
维生素D受体通过CHIP/Sirt6信号通路抑制肠道成纤维细胞活化的机制研究
-
批准号:82300582
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:余梦丽
-
依托单位:
基于压力敏感肾单位微流控芯片的肾上皮细胞CAT1-mTOR通路在梗阻性肾损伤中的作用机制研究
-
批准号:82370678
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:林厚维
-
依托单位:
黄蒲通窍胶囊调控CHIP泛素-蛋白酶体途径降解异常tau蛋白治疗阿尔茨海默病作用机制研究
-
批准号:82374553
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:蔡标
-
依托单位:
Tet2缺失介导的不确定潜能的克隆性造血(CHIP)调控NLRP3/IL-1β在腹主动脉瘤发生发展中的作用和机制
-
批准号:82371594
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:孔祥骞
-
依托单位:
衰老相关蛋白CHIP调控IRP2的分子机制及在多巴胺能神经元退行性变中的作用
-
批准号:82301787
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:贾凤菊
-
依托单位:
PRDX4/FSHR/CHIP轴维护颗粒细胞内质网蛋白质稳态在延缓卵巢功能减退中的分子机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:孟艳
-
依托单位: